

--22. The method of claim 21 wherein the pathology affecting the internal tissues of the eye is selected from pathologies affecting the sclera, ciliary bodies, crystalline lens, vitreous body, and choroidea.--

AM --23. The method of claim 22, wherein the pathology has a trophic, post-traumatic, infective, post-surgical, autoimmune, dystrophic, or degenerative origin, or is originated by laser treatment.--


--24. The method of claim 21, wherein the composition contains from 200-250 µg/ml of nerve growth factor.--

Remarks

The original claims have been cancelled and rewritten in more convention US format.

Respectfully submitted,

By:



Stephen Brown

Registration No. 43,519

N. Whitney Wilson, Esq.

Reg. No. 38,661

BRYAN CAVE LLP

245 Park Avenue

New York, NY 10167

Tel No. (212) 692-1800

Fax No. (212)692-1900